Piramal Pharma's step-down subsidiary Piramal Critical Care B.V. completed acquisition of Kenalog® from Bristol-Myers Squibb.
The acquisition strengthens Piramal's Complex Hospital Generics portfolio across US, Europe, and Asia Pacific markets.
Disclosure filed under Regulation 30 of SEBI Listing Regulations, following earlier intimation dated 28th January, 2026.